When Myeloma Treatment Fails: Understanding Resistance, Relapse, and Your Next Options

Multiple myeloma is highly treatable but rarely curable. Most patients eventually face treatment resistance—relapsed or refractory disease. Understanding why resistance develops helps you navigate the next line of therapy with confidence.

Why Resistance Happens

• Clonal Evolution: Subclones with new mutations survive therapy and expand.
• Microenvironment Protection: Bone marrow stromal cells secrete survival factors that shield myeloma cells.
• Drug Efflux Pumps: Upregulation of transporters like P-glycoprotein ejects drugs from cells.
• Target Modification: Mutations in proteasome subunits (bortezomib resistance) or cereblon (IMiD resistance).
• Phenotypic Plasticity: Plasma cells revert to less differentiated, drug-resistant states.

Clinical Approach to Relapse

1. Confirm Progression: Biochemical (rising M-protein/FLC), imaging, or clinical criteria.
2. Re-Biopsy if Feasible: Repeat FISH/NGS testing may reveal new actionable mutations.
3. Select Next Regimen Based On:
   • Prior therapies and duration of response
   • Current cytogenetics and frailty assessment
   • Novel agents: anti-BCMA therapies (CAR-T, bispecifics), selinexor, belantamab, iberdomide
   • Clinical trial eligibility
4. Goal: Disease control, symptom relief, and quality-of-life preservation.

Relapse is an expected phase of the disease—not a treatment failure. Today's expanding arsenal (7+ drug classes) enables sequential, personalized therapy for years. Stay engaged, ask about trials, and keep moving forward.